Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07321015 2026-01-06

Fzp-MA-TNBC

Phase 2 Not yet recruiting

72 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Phase 2 Not yet recruiting

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07271992 2025-12-09

TREND-02

Phase 2 Not yet recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Phase 2 Not yet recruiting

216 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Phase 2 Not yet recruiting

41 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07080619 2025-09-11

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Phase 2 Not yet recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05806385 2025-09-09

LOGIC

Phase 1/2 Not yet recruiting

36 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

12 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07153965 2025-09-04

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

47 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

59 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Phase 2 Not yet recruiting

125 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07007780 2025-07-29

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Phase 2 Not yet recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06195618 2025-06-25

TEBICA003 TNBC

Phase 1 Not yet recruiting

8 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06819319 2025-06-23

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

52 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07011823 2025-06-10

KEY-MELT

Phase 2 Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms